Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
min-117
- Development stage
- Discontinued
- Lead developer
- Minerva Neurosciences
- Modality
- Multivalent & Scaffold-Based Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
MIN-117 is an investigational small molecule antidepressant developed by Minerva Neurosciences for the treatment of major depressive disorder (MDD). It was originally discovered by Mitsubishi Tanabe Pharma Corporation. The drug acts as an antagonist at serotonin 5-HT1A and 5-HT2A receptors and inhibits the reuptake of serotonin and dopamine. Additionally, it has affinity for alpha 1A and alpha 1B adrenergic receptors and also affects norepinephrine transporters. Clinical trials showed some efficacy in reducing depressive symptoms with a favorable safety profile; however, development for MDD was discontinued after phase IIb trials failed to meet primary endpoints[1][3][4][5][6].
- Other names
- MIN-117MIN117MIN 117WF-516WF516WF 516
02
Targets
ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on min-117.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on min-117.